

Semi-synthesis and biological evaluation of analogues of UK-2A, a novel antifungal antibiotic from *Streptomyces* sp. 517-02

Yoshinosuke Usuki,^{a,*} Koichi Mitomo,^c Noriko Adachi,^a Xu Ping,^b Ken-Ichi Fujita,^b Osamu Sakanaka,^c Katsuharu Inuma,^d Hideo Iio^a and Makoto Taniguchi^{b,*}

^aDepartment of Material Science, Graduate School of Science, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan

^bDepartment of Biology, Graduate School of Science, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan

^cCMC Research Laboratories, Meiji Seika Kaisha Ltd, Kayama, Odawara-shi, Kanagawa 250-0852, Japan

^dFuji Amide Chemical Co., Ltd, Ukima, Kita-ward, Tokyo 115-0051, Japan

Received 17 January 2005; revised 17 February 2005; accepted 19 February 2005

Abstract—Several analogues of UK-2A, a novel antifungal antibiotic isolated from *Streptomyces* sp. 517-02, were semi-synthesized for structure–activity studies. In vitro antifungal activities of these compounds against *Saccharomyces cerevisiae* IFO 0203 were evaluated by the conventional paper disk method. Several derivatives exhibited growth inhibitory activity similar to UK-2A. © 2005 Elsevier Ltd. All rights reserved.

UK-2A is an antifungal antibiotic produced by *Streptomyces* sp. 517-02, and is similar to antimycin A₃ (AA) in both structure and inhibitory activity toward electron transport at complex III in mitochondria.^{1–4} Both UK-2A and AA consist of nine-membered dilactone rings linked via an amide bond to an aromatic acid moiety (Fig. 1); UK-2A possesses a 3-hydroxy-4-methoxypicolinic moiety, while the AAs have 3-formamidosalicylic moieties, reported to be essential for binding to complex III protein and the inhibition of electron transfer between cytochromes *b* and *c*₁ in the mitochondrial respiratory chain.⁵ The benzyl group at the C2 position in UK-2A has not been reported in antimycins and a methyl group is lacking at the C8 position. Furthermore, UK-2A was less cytotoxic than AA against several mammalian cell lines, including murine leukemia P388, murine melanoma B16, porcine renal proximal tubule LLC-PK₁, human oral epidermoid carcinoma KB, and human colon adenocarcinoma COLO201.⁶ As both UK-2A and AA inhibited mitochondrial electron transport, the difference in cytotoxicity between UK-2A and





Figure 1. The structures of UK-2A and AA, showing the focus of SAR.

AA could be attributed to their ability to produce reactive oxygen species.^{6,7} In continuing studies on UK-2A,⁸ we have been interested in establishing structure–activity relations among UK-2A analogues.^{9–11} This study focuses on (1) the 3'-OH group, (2) the benzene moiety, and (3) selective cleavage of the amide bond as shown in Figure 1, and reports the results of preliminary studies on the semi-synthetic preparation and biological evaluation of UK-2A analogues.

Keywords: Antifungal activity; Respiratory inhibition; Structure–activity relationship; Nine-membered dilactone; UK-2A.

* Corresponding authors. Tel.: +81 6 6605 2563; fax: +81 6 6605 2522 (Y.U.); e-mail addresses: usuki@sci.osaka-cu.ac.jp; makoto@sci.osaka-cu.ac.jp



Scheme 3. Chemo-selective cleavage of the amide bond and condensation with *o*-hydroxyl aromatic acids.

heating under reflux for 1.5 h, afforded the imidoyl chloride intermediate, which was then converted to the imino ether with MeOH. Further aqueous work-up gave **B** as a *p*-toluenesulfonic acid salt in 51% yield along with methyl picolinate derivative **A** in 21% yield. Amide formation of **B** with various *o*-hydroxyl aromatic acids was achieved in THF–pyridine with EDC·HCl and HOBT in modest to good yields. The structures of UK-2A derivatives (**12**–**17**) prepared according to this method are presented in [Scheme 3](#).

Compounds **3**–**17**¹⁴ were then evaluated for in vitro antifungal activity against *Saccharomyces cerevisiae* IFO 0203 by the conventional paper disk method using a test medium composed of 1% yeast extract, 2% polypeptone, 3% glycerol, and 2% Bacto-agar. Results are summarized in [Table 1](#).

O-Alkylation products (**3** and **4**) did not inhibit the growth of *S. cerevisiae*, while the *O*-acylated derivatives **5**–**7** showed inhibitory activity less than that exhibited by UK-2A, suggesting that in vivo hydrolysis of **5**–**7** regenerates UK-2A, and the carboxylic group in **7** facilitated smooth reaction. The ether bonds in **3** and **4** are chemically and enzymatically stable and may prevent the regeneration of UK-2A in vivo. The free 3'-OH group is thus essential for the growth inhibitory activity as reported earlier for AA.⁵ Among derivatives with a substituent at the *para* position of the benzene ring (**8**–**11**), the *p*-nitro derivative **8** showed the strongest inhibitory activity; no relation between the electronegativity or basicity of substituents and growth inhibition was found. The replacement of a picolinic acid moiety by salicylic acid derivatives resulted in a slight decrease in the inhibition. 3-Hydroxy-2-quinoxalinecarboxylic acid derivative **12** and 3-hydroxy-6-methoxypicolinic acid derivative **13** showed inhibitory activity similar to

UK-2A, suggesting that substitutions at the 5'- and/or 6'-position of picolinic acid are not effective promoters of growth inhibitory activity.

In summary, chemical modifications of the 3'-OH group revealed that the free hydroxyl group at the 3' position is necessary for the inhibitory activity in UK-2A as well as AAs. Nitration at the *para* position of the benzene moiety and chemo-selective cleavage of the amide bond were achieved in good yields without decomposition of the nine-membered dilactone ring of UK-2A. *p*-Amino derivative **9** is a suitable precursor for photoaffinity-labeled

Table 1. Antifungal activity of UK-2A, AA, and their derivatives (**3**–**17**)^a

Compounds	Dose (μg/disc)			
	0.025	0.05	0.125	0.25
UK-2A (1)	19	22	26	26
AA (2)	16	18	19	26
3	0	0	0	0
4	0	0	0	0
5	10	12	14	18
6	8	10	15	18
7	12	16	21	24
8	12	15	18	20
9	0	0	8	10
10	0	0	0	0
11	0	11	15	19
12	14	18	20	24
13	16	19	24	27
14	0	12	16	17
15	8	8	11	12
16	8	12	16	17
17	8	8	12	14

^a Values are stated in diameter of inhibitory zone around the discs (mm).

analogues designed for elucidating the UK-2A binding site on mitochondria.

Acknowledgements

This research was partially supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (nos. 12556017 and 14580615), which are gratefully appreciated.

References and notes

1. Ueki, M.; Abe, K.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. *J. Antibiot.* **1996**, *49*, 639.
2. Hanafi, M.; Shibata, K.; Ueki, M.; Taniguchi, M. *J. Antibiot.* **1996**, *49*, 1226.
3. Ueki, M.; Taniguchi, M. *J. Antibiot.* **1997**, *50*, 1052.
4. Shibata, K.; Hanafi, M.; Fujii, J.; Sakanaka, O.; Inuma, M.; Ueki, M.; Taniguchi, M. *J. Antibiot.* **1998**, *51*, 1113.
5. Tokutake, N.; Miyoshi, H.; Satoh, T.; Hatano, T.; Iwamura, H. *Biochim. Biophys. Acta* **1994**, *1185*, 271.
6. Takimoto, H.; Akimoto, H.; Machida, K.; Ueki, M.; Tanaka, T.; Taniguchi, M. *J. Antibiot.* **1999**, *52*, 480.
7. Machida, K.; Takimoto, H.; Miyoshi, H.; Taniguchi, M. *J. Antibiot.* **1999**, *52*, 748.
8. For a review, see: Ueki, M.; Machida, K.; Taniguchi, M. *Curr. Opin. Anti-infective Invest. Drugs* **2000**, *2*, 387.
9. Usuki, Y.; Tani, K.; Fujita, K.-I.; Taniguchi, M. *J. Antibiot.* **2001**, *54*, 600.
10. Usuki, Y.; Goto, K.; Kiso, T.; Tani, K.; Ping, X.; Fujita, K.-I.; Taniguchi, M. *J. Antibiot.* **2002**, *55*, 607.
11. Fujita, K.-I.; Kiso, T.; Usuki, Y.; Tanaka, T.; Taniguchi, M. *J. Antibiot.* **2004**, *57*, 687.
12. Fechtig, B.; Peter, H.; Bickel, H.; Vischer, E. *Helv. Chim. Acta* **1968**, *51*, 1108.
13. Weissenburger, H. W. O.; van der Hoeven, M. G. *Recl. Trav. Chim. Pays-Bas* **1970**, *89*, 1081.
14. The identity and purity of all new compounds were established by ¹H NMR and MS.